glp-1 agonist moa Frontiers The dual glucose-dependent insulinotropic polypeptide
Description
Physicians on Sermo share experiences with GLP-1 weight loss drugs and risks
Discover what current research and FDA findings reveal about mental health risks with semaglutide, tirzepatide, and other GLP-1 medications for diabetes and weight management.
Learn how low-dose semaglutide and tirzepatide may support metabolism, menopause, inflammation, and autoimmune health.
Berberine and GLP-1 are fundamentally different compounds targeting distinct metabolic pathways
A comprehensive phase 3 program is ongoing to evaluate efficacy, safety, and cardiovascular/renal outcomes in people with obesity and/or T2D
